CARF Office-Based Opioid Treatment (OBOT) Accreditation — Frequently Asked Questions

Last updated: April 2026

IHS answers the most common questions about CARF OBOT accreditation — from eligibility and standards to timeline, fees, and how OBOT differs from OTP accreditation. For program-specific questions, schedule a free Discovery Session with our consulting team.

What is CARF Office-Based Opioid Treatment (OBOT) accreditation?

CARF OBOT accreditation is a voluntary quality recognition for programs that treat opioid use disorder (OUD) with buprenorphine or naltrexone in an office-based setting, combined with counseling and psychosocial support services. CARF introduced dedicated OBOT standards in its 2019 Behavioral Health Standards Manual — the first national accreditation framework designed specifically for office-based MOUD programs. Unlike federally regulated Opioid Treatment Programs (OTPs), OBOT programs do not dispense methadone.

What is the difference between CARF OBOT accreditation and CARF OTP accreditation?

CARF OTP accreditation applies to federally regulated Opioid Treatment Programs that dispense methadone (and may also offer buprenorphine and naltrexone). OTPs require SAMHSA certification in addition to CARF accreditation and are subject to 42 CFR Part 8 federal regulations, DEA Schedule II narcotic dispensing oversight, and mandatory daily observed dosing protocols.

CARF OBOT accreditation applies to office-based programs that prescribe buprenorphine or naltrexone only — no methadone dispensing. OBOT programs operate under standard DEA prescribing authority (Schedule III for buprenorphine) and do not require SAMHSA certification. The standards frameworks, survey scope, and regulatory overlays are substantially different.

Is CARF OBOT accreditation required or voluntary?

CARF OBOT accreditation is voluntary at the federal level. There is no federal mandate requiring physician offices or FQHCs to obtain CARF accreditation to prescribe buprenorphine. However, accreditation is increasingly required or preferred by state behavioral health authorities for contracting, by Medicaid managed care organizations for network participation, and by opioid settlement grant programs for funding eligibility. Organizations should verify specific state and payer requirements.

Who is eligible to apply for CARF OBOT accreditation?

Any organization operating an office-based program that combines buprenorphine or naltrexone prescribing for OUD with counseling and psychosocial services is eligible. This includes:

• Physician offices and group medical practices
• Federally Qualified Health Centers (FQHCs)
• Behavioral health clinics
• Integrated behavioral health programs within health systems
• Certified Community Behavioral Health Clinics (CCBHCs)
• Rural health clinics
• Telehealth MOUD programs

Programs that prescribe buprenorphine without any structured counseling or psychosocial services component generally do not meet CARF's OBOT program definition.

What standards does CARF evaluate in an OBOT survey?

CARF evaluates OBOT programs against standards drawn from the Behavioral Health Standards Manual covering five core areas:

• Program definition and scope — written definition of populations served, medications used, and services provided or arranged
• Medical director qualifications and oversight — current licensure, addiction medicine training or experience, and documented clinical governance activity
• Psychosocial support services — individual counseling, group therapy or peer support, case management, and referral pathways for co-occurring disorders
• Clinical procedures for induction, stabilization, maintenance, and monitoring — written protocols for each treatment phase, urine drug screening, dosing decisions, and diversion prevention
• Staff training and competency — documented OUD-specific training, trauma-informed care, and overdose response competency for all staff

What did the 2025 CARF standards update change for OBOT programs?

CARF's 2025 Behavioral Health Standards Manual (effective July 1, 2025 through June 30, 2026) introduced Standard 2.A.12, which requires organizations to develop a written procedure for Measurement-Informed Care (MIC). For OBOT programs, this means documenting how validated clinical outcome tools are selected, administered, scored, and used in treatment decision-making. Programs must show at least two comparison data points and evidence that outcome data is used in quality improvement decisions. Programs that collect screening scores without analyzing trends or feeding data back into care planning will be cited under this standard.

How long does it take to prepare for CARF OBOT accreditation?

Most physician offices and FQHCs pursuing initial CARF OBOT accreditation complete preparation in 9–18 months. The primary variables are existing documentation maturity, whether a quality management infrastructure is already in place, and staff bandwidth. Organizations with strong existing policies, active quality programs, and dedicated administrative support can move faster. Programs building infrastructure from scratch typically need the full 12–18 months. IHS begins every engagement with a gap assessment that produces a realistic timeline specific to the organization's starting point.

What are CARF's accreditation fees for OBOT programs?

Published by CARF in the annual fee schedule (carf.org): application fee $995 (non-refundable); survey fee $1,525 per surveyor per day. The number of surveyor days is determined by CARF based on program size and scope. Verify current fees with CARF before budgeting — fees are updated annually. IHS consulting engagements are scoped to each client's organizational size, accreditation history, and complexity.

Does eliminating the X-Waiver (DATA 2000 waiver) affect CARF OBOT accreditation?

The Consolidated Appropriations Act of 2023 (signed December 29, 2022) eliminated the DATA 2000 X-Waiver requirement. Since then, any DEA-registered practitioner with Schedule III authority can prescribe buprenorphine for OUD without a separate waiver, subject to applicable state law. This expanded the pool of potential OBOT providers significantly but does not change CARF's OBOT accreditation standards. Programs still need to meet CARF's requirements for medical director oversight, psychosocial services, clinical procedures, staff training, and Measurement-Informed Care.

Does a new 8-hour training requirement apply to OBOT providers?

Yes. Section 1263 of the Consolidated Appropriations Act of 2023 requires new or renewing DEA registrants (starting June 27, 2023) to complete at least 8 hours of training on opioid or other substance use disorders when applying for or renewing any DEA registration to prescribe Schedule II–V controlled medications. For CARF OBOT purposes, training completion should be documented in the medical director's and prescribing clinicians' personnel files as part of the staff training and competency domain.

What is the most common reason OBOT programs fail CARF surveys?

The most common citations include: outcome data collected but never analyzed or used in quality decisions; inadequate documentation of psychosocial service arrangements; personnel file gaps including lapsed credentials, missing training records, and unsigned job descriptions; clinical procedures that exist on paper but are not operationally practiced; and medical director involvement that is real but undocumented. A comprehensive mock survey and personnel file audit before submitting the CARF application addresses most of these issues before the actual survey.

Can a telehealth MOUD program obtain CARF OBOT accreditation?

Yes. CARF OBOT standards do not restrict accreditation to in-person delivery. Telehealth MOUD programs prescribing buprenorphine or naltrexone and providing counseling and psychosocial services via telehealth can pursue CARF OBOT accreditation. Programs should document their telehealth-specific clinical procedures, informed consent processes, and state telehealth prescribing compliance as part of accreditation preparation.

Does CARF OBOT accreditation cover naltrexone (Vivitrol) programs?

Yes. CARF's OBOT accreditation covers programs using either buprenorphine or naltrexone — including injectable extended-release naltrexone (Vivitrol) — for OUD treatment. Naltrexone is an opioid antagonist and not a controlled substance, so its prescribing does not require DEA registration. Programs offering naltrexone as the primary or sole MOUD alongside counseling and psychosocial services meet CARF's OBOT program definition.

How does CARF OBOT accreditation relate to CCBHC certification?

Certified Community Behavioral Health Clinics are required to provide or arrange access to medications for opioid use disorder as part of their required service array. CARF is the only accreditation body approved by SAMHSA to certify organizations against CCBHC criteria. CCBHCs operating an OBOT program can strengthen their MOUD access documentation and consolidate accreditation and certification with a single body. IHS works with CCBHCs on both CARF CCBHC certification and OBOT program accreditation.

What psychosocial services does CARF require OBOT programs to provide or arrange?

CARF requires OBOT programs to provide or arrange for individual counseling, access to group therapy or peer support, case management or care coordination, and referral pathways for co-occurring mental health disorders and social determinants of health needs. Programs do not need to deliver all services in-house — formal referral agreements with community providers can satisfy the "arrange for" requirement. However, those arrangements must be documented, and staff must demonstrate knowledge of how to connect patients to those services.

What happens after CARF OBOT accreditation is awarded?

CARF OBOT accreditation is awarded for a three-year term. During the cycle, the organization must implement any Quality Improvement Plan responding to cited standards and continue operating in conformance with CARF standards. CARF does not charge annual maintenance fees — all costs are concentrated at the application and survey events. IHS supports post-award QIP implementation and ongoing compliance monitoring throughout the accreditation cycle.

How does IHS support CARF OBOT accreditation preparation?

IHS provides end-to-end CARF OBOT accreditation consulting across three practice lines: Accreditation Consulting (gap assessment, policy development, mock survey, QIP support), Compliance Services (ongoing regulatory monitoring), and Program Development (designing new OBOT programs for accreditation readiness from launch). IHS is led by Thomas G. Goddard, JD, PhD, former COO and General Counsel of URAC, with over 25 years of accreditation and compliance consulting experience.

Schedule a Free Discovery Session